Sort   by:  
 Page size 
UnknownAn analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.
Not available
S-EPMC5653730 | biostudies-literature
UnknownDifferent methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Not available
S-EPMC7809812 | biostudies-literature
UnknownDiverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Not available
S-EPMC11724937 | biostudies-literature
UnknownSurvival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
Not available
S-EPMC10162955 | biostudies-literature
UnknownEuropean LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Not available
S-EPMC8864653 | biostudies-literature
UnknownUse of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience.
Not available
S-EPMC8997036 | biostudies-literature
UnknownUnique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia.
Not available
S-EPMC7271589 | biostudies-literature
UnknownA pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.
Not available
S-EPMC7131850 | biostudies-literature
UnknownGenetic evolution and relapse-associated mutations in adult T-cell acute lymphoblastic leukemia patients treated in PETHEMA trials.
Not available
S-EPMC12104817 | biostudies-literature
UnknownP1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL
Not available
S-EPMC10431106 | biostudies-literature
Sort   by:  
 Page size